Archives: Company News
Company news stories
SIU 2025: Dr. Seth Lerner Presents Immune Response and Preliminary Efficacy of bel-sar (AU-011), a first-in-class virus-like drug conjugate (VDC), in NMIBC
EAU 2025: Research Forum – Virus-like Drug Conjugates (VDC), a paradigm shifting approach for the treatment of bladder cancer Mechanism, First Insights, and Future Directions
EAU 2025: Dr. Lerner Presents Safety and efficacy of Bel-sar (AU-011), a Virus-like-Drug-Conjugate (VDC) in patients with Non-Muscle Invasive Bladder Cancer (NMIBC)
Retina Society 2024: Dr. Kim Presents Final Results of a Phase 2 Trial of Suprachoroidal Administration of Bel-sar for Choroidal Melanoma
ARVO 2024: Dr. Ma Presents Preclinical Belzupacap Sarotalocan Data for Cancers of the Ocular Surface
Treatment of conjunctival melanoma cell lines with Bel-Sar induces immunogenic cell death
AAO 2023: Dr. Shields Presents Phase 2 SC Belzupacap Sarotalocan Data
A Phase 2 Trial of Belzupacap Sarotalocan, a Targeted Investigational Therapy for Choroidal Melanoma via Suprachoroidal Administration
IPVC 2023: Dr Kines Presents cVDC Data
A novel immunotherapy for the treatment of HPV+ tumors based on a chimeric Virus-like Drug Conjugate
AACR 2023: Dr. Kines Presents cVDC Data
A novel chimeric virus-like drug conjugate for the potential treatment of HPV+ tumors
ARVO 2023: Dr. Ma Presents Preclinical Belzupacap Sarotalocan Data
The role of pigmentation in tumor treatment with virus-like drug conjugate belzupacap sarotalocan (AU-011) in an vitro and vivo model